Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAS-205 in Duchenne Muscular Dystrophy
NCT02752048Phase 2Completed
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- May 2016
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of pizuglanstat in Duchenne muscular dystrophy (DMD) (3 arms), sponsored by Taiho Pharmaceutical Co., Ltd. Primary endpoint: 6-minute Walk Distance at 24 weeks. Started May 2016; status: completed.
02
Drugs
pizuglanstat
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT02752048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02752048.